Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.

We report a case with a complete pathology-proven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma. A significant objective response was observed with tumor size reduction during treatment. After surgery, on pathologic examination it was concluded that the patient exhibited a complete response; activity and the feasibility and safety of subsequent surgical resection were assessed. Otherwise after discontinuing sunitinib, the patient had a relapse on the same location; sunitinib has been resumed and was again found to be effective.
AuthorsMaria Angeles Vaz, Vanessa Pachón, Enrique Grande, Reyes Ferreiro, Alfredo Carrato
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 22 Issue 8 Pg. 817-21 (Sep 2011) ISSN: 1473-5741 [Electronic] England
PMID21566523 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • sunitinib
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Renal Cell (drug therapy, pathology, surgery)
  • Combined Modality Therapy
  • Humans
  • Indoles (therapeutic use)
  • Kidney Neoplasms (drug therapy, pathology, surgery)
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Pyrroles (therapeutic use)
  • Remission Induction (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: